Atria Investments Inc trimmed its stake in shares of CME Group Inc. (NASDAQ:CME - Free Report) by 13.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,050 shares of the financial services provider's stock after selling 4,370 shares during the quarter. Atria Investments Inc's holdings in CME Group were worth $6,410,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also added to or reduced their stakes in CME. Wealth Enhancement Advisory Services LLC grew its stake in CME Group by 21.2% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 48,205 shares of the financial services provider's stock valued at $9,477,000 after acquiring an additional 8,443 shares during the period. Cetera Investment Advisers grew its stake in CME Group by 429.1% in the first quarter. Cetera Investment Advisers now owns 47,521 shares of the financial services provider's stock valued at $10,231,000 after acquiring an additional 38,540 shares during the period. Brookstone Capital Management boosted its position in shares of CME Group by 12.2% during the second quarter. Brookstone Capital Management now owns 30,555 shares of the financial services provider's stock valued at $6,156,000 after buying an additional 3,325 shares during the last quarter. TD Asset Management Inc boosted its position in shares of CME Group by 16.1% during the first quarter. TD Asset Management Inc now owns 371,849 shares of the financial services provider's stock valued at $80,055,000 after buying an additional 51,689 shares during the last quarter. Finally, Epoch Investment Partners Inc. boosted its position in shares of CME Group by 4.7% during the first quarter. Epoch Investment Partners Inc. now owns 99,947 shares of the financial services provider's stock valued at $21,518,000 after buying an additional 4,454 shares during the last quarter. 87.75% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several research firms have weighed in on CME. Piper Sandler boosted their price objective on CME Group from $240.00 to $250.00 and gave the stock an "overweight" rating in a research report on Monday, October 28th. TD Cowen began coverage on CME Group in a research note on Thursday, September 26th. They set a "hold" rating and a $221.00 price objective on the stock. Barclays boosted their target price on CME Group from $219.00 to $231.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 24th. Redburn Atlantic cut CME Group from a "buy" rating to a "neutral" rating and set a $244.00 price objective for the company. in a report on Tuesday, October 8th. Finally, Citigroup increased their target price on CME Group from $250.00 to $255.00 and gave the company a "buy" rating in a report on Thursday, October 24th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $224.47.
View Our Latest Stock Analysis on CME Group
Insiders Place Their Bets
In other CME Group news, Director Bryan T. Durkin sold 7,593 shares of the firm's stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $214.59, for a total transaction of $1,629,381.87. Following the sale, the director now owns 55,607 shares of the company's stock, valued at approximately $11,932,706.13. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Bryan T. Durkin sold 7,593 shares of the business's stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $214.59, for a total value of $1,629,381.87. Following the completion of the transaction, the director now owns 55,607 shares of the company's stock, valued at approximately $11,932,706.13. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Timothy Francis Mccourt sold 1,374 shares of the business's stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $227.12, for a total transaction of $312,062.88. Following the completion of the transaction, the insider now directly owns 7,275 shares of the company's stock, valued at $1,652,298. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 15,621 shares of company stock valued at $3,441,063. 0.30% of the stock is owned by corporate insiders.
CME Group Stock Performance
NASDAQ:CME traded up $0.38 during mid-day trading on Tuesday, hitting $226.31. The company's stock had a trading volume of 1,496,422 shares, compared to its average volume of 1,913,746. CME Group Inc. has a 1 year low of $190.70 and a 1 year high of $230.36. The company has a debt-to-equity ratio of 0.09, a current ratio of 1.02 and a quick ratio of 1.02. The stock has a market cap of $81.49 billion, a price-to-earnings ratio of 23.76, a PEG ratio of 5.68 and a beta of 0.55. The business's fifty day moving average is $221.92 and its two-hundred day moving average is $209.93.
CME Group (NASDAQ:CME - Get Free Report) last released its quarterly earnings results on Wednesday, October 23rd. The financial services provider reported $2.68 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.03. The firm had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.59 billion. CME Group had a net margin of 57.34% and a return on equity of 13.39%. The company's revenue for the quarter was up 18.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.25 EPS. Analysts anticipate that CME Group Inc. will post 10.23 EPS for the current fiscal year.
CME Group Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, December 27th. Investors of record on Monday, December 9th will be issued a $1.15 dividend. The ex-dividend date of this dividend is Monday, December 9th. This represents a $4.60 annualized dividend and a yield of 2.03%. CME Group's dividend payout ratio (DPR) is 48.37%.
About CME Group
(
Free Report)
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.
See Also
Before you consider CME Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.
While CME Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
